- Conditions
- Degenerative Spine Disease
- Interventions
- FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute, Demineralized Bone Matrix
- Device
- Lead sponsor
- DePuy Synthes Products, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Sacramento, California • Chicago, Illinois • Lexington, Kentucky + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 133
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
- Drug · Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Degenerative Disc Disease
- Interventions
- Avenue® L Interbody Fusion System (LDR Spine)
- Device
- Lead sponsor
- LDR Spine USA
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Thornton, Colorado • Atlanta, Georgia • Neptune City, New Jersey + 1 more
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- Interventions
- KRT-232, acalabrutinib
- Drug
- Lead sponsor
- Kartos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- RO7496353, Atezolizumab, Capecitabine, S-1, Nivolumab, Oxaliplatin, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania
- Conditions
- Movement Disorders (Incl Parkinsonism), Stroke, Traumatic Brain Injury, Brain Diseases, Parkinson Disease, Essential Tremor, Movement Disorders
- Interventions
- Direct cortical stimulation and deep brain stimulation of motor thalamus
- Device
- Lead sponsor
- Jorge Gonzalez-Martinez
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Acute Myeloid Leukemia
- Interventions
- TL-895, KRT-232
- Drug
- Lead sponsor
- Telios Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Orange, California • Augusta, Georgia + 7 more
- Conditions
- Transforaminal Lumbar Interbody Fusion Surgery
- Interventions
- Nerve Cuff and Retractor System
- Device
- Lead sponsor
- Retropsoas Technologies, LLC
- Industry
- Eligibility
- 22 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- Bemarituzumab, CAPOX, SOX, Nivolumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Northport, New York
- Conditions
- Degenerative Disc Disease
- Interventions
- completion of the (VAS) for level of back pain, completion of the (OLBPQ) for assessment of function
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Interventions
- Lifileucel, LN-145, Pembrolizumab, LN-145-S1, Ipilimumab, Nivolumab, Nivolumab-relatlimab, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 20
- States / cities
- La Jolla, California • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Mucositis, Head and Neck Cancer
- Interventions
- Saline, Traumeel S
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Sacroiliac Joint Complex, Low Back Pain
- Interventions
- Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA), Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
- Procedure
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Farmington, Utah • Salt Lake City, Utah • South Jordan, Utah
- Conditions
- COVID-19
- Interventions
- Aluminum Hydroxide Suspension, Boost-2867, CpG 7909, Sodium Chloride, 0.9%
- Drug · Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 8
- States / cities
- San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more
- Conditions
- Degenerative Disc Disease, Scoliosis
- Interventions
- Oblique Lateral Interbody Fusion
- Procedure
- Lead sponsor
- Medtronic Spinal and Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Murrieta, California • San Francisco, California • Melbourne, Florida + 3 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Low Back Pain, Chronic
- Interventions
- Iovera Medial Branch Cryoneurolysis, Radiofrequency ablation (RFA)
- Device · Procedure
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Spinal Cord Injuries, Spinal Cord Diseases, Trauma, Nervous System, Nervous System Diseases, Central Nervous System Diseases, Hypotension, Orthostatic Hypotension, Cardiovascular Diseases, Acute Spinal Cord Injury, Blood Pressure
- Interventions
- Orthostatic challenge, Biostim-5 transcutaneous spinal stimulation - Mapping, Biostim-5 transcutaneous spinal stimulation - "Optimal" testing, Biostim-5 transcutaneous spinal stimulation - "Sham" testing
- Diagnostic Test · Device
- Lead sponsor
- Kessler Foundation
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Medulloblastoma
- Interventions
- Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 59 Months
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2035
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
- Conditions
- Stroke, Aphasia, Motor Speech
- Interventions
- Melodic Intonation Therapy, Video Feedback Performance Review
- Behavioral
- Lead sponsor
- Nevada State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Henderson, Nevada
- Conditions
- Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
- Interventions
- Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
- Biological · Other · Drug
- Lead sponsor
- Beat AML, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
- Conditions
- Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
- Interventions
- KRT-232
- Drug
- Lead sponsor
- Kartos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 6 more
- Conditions
- Spinal Diseases
- Interventions
- A-MAV™ disc
- Device
- Lead sponsor
- Medtronic Spinal and Biologics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 3
- States / cities
- Columbus, Georgia • Chesterfield, Missouri • Austin, Texas
- Conditions
- Chronic Low-back Pain
- Interventions
- Real tACS, Sham tACS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts